A wnaiff y Gweinidog Cabinet gadarnhau a yw dyfeisiau niwrofodiwleiddio Neupulse, a ddefnyddir ar gyfer rheoli syndrom Tourette ac anhwylderau ticiau cronig, yn cael eu hasesu ar hyn o bryd, neu'n cael eu cynnwys ar unrhyw restrau caffael, cyllid neu ddosbarthu cenedlaethol ar gyfer GIG Cymru?
Neupulse neuromodulation devices are not currently included on any national procurement, funding or distribution lists for NHS Wales. The technology is, however, subject to ongoing evidence generation through a National Institute for Health and Care Excellence (NICE) Early Value Assessment published in May 2025. NICE has advised that, following a three-year evidence generation period, the available evidence will be reviewed to determine whether the technology is suitable for routine adoption within the NHS. Information published by the manufacturer also indicates that the device is subject to ongoing development as it continues to progress through regulatory and evidence-generation processes.